The 8 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 6.50, with a high estimate of 13.00 and a low estimate of 4.00. The median estimate represents a +232.48% increase from the last price of 1.96.
The current consensus among 9 polled investment analysts is to Buy stock in BioCryst Pharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.25
Reporting Date May 07
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.